These could be explained by that EPO that was used in cTACE might lead to fast escape and metabolization of cytotoxic drugs, hence increased the toxicity to normal liver tissues and adjacent organs, thereby aggravating liver function injury and adverse events in huge HCC patients. The gene discussed is EPO; the disease is hepatocellular carcinoma.